Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript

🇺🇸 Seeking Alpha (US) —

AI Summary

Capricor Therapeutics discussed data from the HOPE-3 open-label extension and provided an update on deramiocel for Duchenne muscular dystrophy. The transcript concerns the company's clinical development program; the supplied description provides no further details on the results.

Markets Health Capricor Therapeutics deramiocel Duchenne muscular dystrophy HOPE-3 clinical development

Read original source →